How to incorporate MRI into your CKD clinical trials – International Renal Imaging Meeting

Iris Friedli, Senior Director MR Imaging at Antaros Medical, has been invited to speak at the 5th International Renal Imaging Meeting. The meeting, organised by, is being held in Ghent, Belgium on September 11-12, 2023.

Chronic kidney disease (CKD), the gradual loss of kidney function, is estimated to affect 8-10% of the world’s adult population. There is an urgent need for biomarkers, as those currently used do not provide insights into the pathophysiology, degree of anatomical damage, or risk of progression. Magnetic Resonance Imaging (MRI) is a non-invasive imaging technique with the potential to fill this need.

Using MRI allows us to advance our understanding of kidney microstructure, macrostructure, oxygenation, and hemodynamics. A multiparametric MRI protocol can incorporate this into a single exam, which can be especially valuable in clinical trials for drug development, as treatment effects can be studied directly.

However, there are many important factors to be considered when incorporating MRI into a CKD clinical trial, particularly for large, international, multi-centre trials. In order to have confidence in the imaging results from your clinical trial, protocols need to be thoughtfully designed, sites need to be trained and managed effectively, and results need to be interpreted in the context of the relevant biology. Iris will be discussing this further in her presentation ‘Clinical trials on added value of MRI in CKD’.

Presentation title: Clinical trials on added value of MRI in CKD
Session title: 5th Session – CKD Imaging
Speaker: Iris Friedli
Date and time: Tuesday September 12, 9:00-9:20 CEST

You can see the entire meeting program on the website.

Share on Linkedin Share on Twitter